Stay updated with breaking news from Pharma marketing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
After a very public back-and-forth over COVID-19 vaccine supplies in Europe earlier this year, AstraZeneca said it would aim to deliver 40 million doses in the first quarter. It’s now rolling the estimate back to 30 million, Reuters reports the same figure that triggered the initial controversy. Meanwhile, in some countries, doses are going unused. ....
Mar 11, 2021 12:08pm Who will lead the FDA under President Joe Biden? Former FDA chiefs are urging Biden to hurry up and make a choice. (FDA) The clock is ticking on an FDA commissioner nomination, with public pressure on President Joe Biden to pick up the pace. Six former FDA commissioners wrote the White House this week urging Biden to make a choice, according to several media reports. The letter, signed by Robert Califf, Scott Gottlieb, Margaret Hamburg, Jane Henney, Mark McClellan and Andrew von Eschenbach, pushed Biden to act in the face of the ongoing coronavirus pandemic. They noted vaccine, drug and testing issues related to the pandemic, as well as the need to implement new tobacco regulations, according to The Washington Post. ....
Europe's COVID-19 immunization campaign has been challenged by early supply problems and now safety concerns for AstraZeneca’s shot. A fourth vaccine is now on its way though it's not going to fix the supply shortfall immediately. ....
AstraZeneca’s coronavirus vaccine is facing a wave of mistrust in Europe a striking difference from its stellar reputation in the U.K. While 81% of Britons believe the AZ vaccine is safe, which is on par with similar 79% of U.K. citizens who trust of the Pfizer vaccine, only 43% of Germans and 33% of French citizens consider it safe, accoriding to a surveyed by YouGov. ....
AstraZeneca’s COVID-19 vaccine rollout has gotten off to a rocky start in Europe. First, a supply shortfall triggered a public back-and-forth between executives and government officials. Then, several countries raised efficacy doubts for people over 65. Now some countries are raising safety concerns. ....